All In Biotech

Drug Trial Radar · NCT05645107

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY® Plus Standard Medical Treatment Compared to Placebo Plus Standard Medical Treatment to Prevent Infections in Patients With Hypogammaglobulinemia and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 386 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

386

Planned (sponsor's estimate)

Start

Dec 26, 2022

Primary completion

Aug 2029

Study completion Aug 2029

Sponsor

Lead sponsor
Grifols Therapeutics LLCIndustry
Sponsor type
Industry
First posted
Dec 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in B-cell CLL, MM, and NHL participants with hypogammaglobulinemia (HGG) in comparison to the Placebo plus SMT group.

Conditions

  • Hypogammaglobulinemia
  • Bacterial Infections
  • B-cell Chronic Lymphocytic Leukemia
  • Multiple Myleoma
  • Non-Hodgkin Lymphoma

Interventions

  • XembifyDrug

    SC infusion pump

  • PlaceboDrug

    SC infusion pump

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annual Rate of Major Bacterial Infections per YearTime frame: Up to Week 51

Locations

62 sites in 8 countries. Site status is shown where the registry gives one.

  • GC2202 Study Site 118

    Bullhead City, Arizona · Recruiting

  • GC2202 Study Site 115

    Huntington Park, California · Recruiting

  • GC2202 Study Site 103

    St. Petersburg, Florida · Recruiting

  • GC2202 Study Site 111

    Bethesda, Maryland · Recruiting

  • GC2202 Study Site 109

    Greenville, North Carolina · Recruiting

  • GC2202 Decentralized Study Site 114

    Morrisville, North Carolina · Recruiting

  • GC2202 Study Site 117

    Wilson, North Carolina · Recruiting

  • GC2202 Study Site 105

    Canton, Ohio · Recruiting

  • GC2202 Study Site 110

    Rockville, South Carolina · Withdrawn

  • GC2202 Study Site 702

    Banja Luka, Bosnia and Herzegovina · Recruiting

  • GC2202 Study Site 703

    Mostar, Bosnia and Herzegovina · Recruiting

  • GC2202 Study Site 701

    Sarajevo, Bosnia and Herzegovina · Not yet recruiting

  • GC2202 Study Site 202

    Burgas, Bulgaria · Recruiting

  • GC2202 Study Site 203

    Plovdiv, Bulgaria · Recruiting

  • GC2202 Study Site 210

    Plovdiv, Bulgaria · Recruiting

  • GC2202 Study Site 205

    Rousse, Bulgaria · Recruiting

  • GC2202 Study Site 209

    Sofia, Bulgaria · Recruiting

  • GC2202 Study Site 201

    Sofia, Bulgaria · Recruiting

  • GC2202 Study Site 206

    Sofia, Bulgaria · Recruiting

  • GC2202 Study Site 207

    Sofia, Bulgaria · Recruiting

  • GC2202 Study Site 211

    Sofia, Bulgaria · Recruiting

  • GC2202 Study Site 212

    Sofia, Bulgaria · Recruiting

  • GC2202 Study Site 213

    Sofia, Bulgaria · Recruiting

  • GC2202 Study Site 204

    Sofia, Bulgaria · Recruiting

  • GC2202 Study Site 208

    Sofia, Bulgaria · Recruiting

  • GC2202 Study Site 214

    Stara Zagora, Bulgaria · Recruiting

  • GC2202 Study Site 801

    Rijeka, Croatia · Recruiting

  • GC2202 Study Site 802

    Zagreb, Croatia · Recruiting

  • GC2202 Study Site 301

    Budapest, Hungary · Recruiting

  • GC2202 Study Site 308

    Budapest, Hungary · Recruiting

  • GC2202 Study Site 306

    Debrecen, Hungary · Recruiting

  • GC2202 Study Site 304

    Eger, Hungary · Recruiting

  • GC2202 Study Site 302

    Győr, Hungary · Recruiting

  • GC2202 Study Site 307

    Szeged, Hungary · Recruiting

  • GC2202 Study Site 303

    Szekszárd, Hungary · Recruiting

  • GC2202 Study Site 305

    Székesfehérvár, Fejér, Hungary · Withdrawn

  • GC2202 Study Site 408

    Bydgoszcz, Poland · Recruiting

  • GC2202 Study Site 410

    Krakow, Poland · Recruiting

  • GC2202 Study Site 409

    Olsztyn, Poland · Recruiting

  • GC2202 Study Site 407

    Torun, Poland · Withdrawn

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.